Journal
NPJ VACCINES
Volume 7, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41541-022-00550-5
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases (MIDAS Program) of the National Institutes of Health [R01AI137093]
Ask authors/readers for more resources
Several RSV prevention strategies, including maternal immunization and long-lasting monoclonal antibodies (mAbs), show promise in preventing RSV hospitalizations in infants under 6 months of age. Live-attenuated vaccines can reduce hospitalizations in vaccinated age groups and have a modest effect in unvaccinated age groups as well.
Several vaccines and extended half-life monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) have shown promise in clinical trials. We used age-structured transmission models to predict the possible impact of various RSV prevention strategies including maternal immunization, live-attenuated vaccines, and long-lasting mAbs. Our results suggest that maternal immunization and long-lasting mAbs are likely to be highly effective in preventing RSV hospitalizations in infants under 6 months of age, averting more than half of RSV hospitalizations in neonates. Live-attenuated vaccines could reduce RSV hospitalizations in vaccinated age groups and are also predicted to have a modest effect in unvaccinated age groups because of disruptions to transmission. Compared to year-round vaccination, a seasonal vaccination program at the country level provides at most a minor advantage regarding efficiency. Our findings highlight the substantial public health impact that upcoming RSV prevention strategies may provide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available